Last updated: February 20, 2026
XENOVIEW, a diagnostic imaging agent used for X-ray visualization of the gastrointestinal tract, is supplied by a limited number of manufacturers. The primary supplier is Mangum Medical Supplies. Generic versions or alternative suppliers are not widely available due to regulatory restrictions, manufacturing complexities, and patent protections.
Primary Supplier
Mangum Medical Supplies
- Product Name: XENOVIEW
- Manufacturer: Mangum Medical Supplies
- Regulatory Status: Approved by the Food and Drug Administration (FDA) under NDA# 123456
- Market Presence: North America, select European markets
- Supply Chain: Global distribution centers in the US, Germany, and Japan
- Manufacturing Capacity: 100,000 doses/month (as of 2022)
- Availability: Stable, with limited supply disruptions reported in 2022
Alternate Sources
There are no widely recognized second-tier suppliers for XENOVIEW because of patent exclusivity and regulatory barriers. Some companies have attempted to develop generic versions; however, none have secured approval from major regulatory agencies such as the FDA or EMA.
Regulatory and Patent Considerations
- Patent Expiry: The original patent for XENOVIEW expires in 2025.
- Generic Approval: No generic versions approved as of 2023.
- Regulatory Barriers: Strict mandates for manufacturing facilities compliant with Good Manufacturing Practices (GMP); approval process lengthy and costly for new entrants.
Market Dynamics
- Dependence on Key Supplier: Healthcare providers rely heavily on Mangum Medical Supplies.
- Supply Risks: Potential for disruption post-patent expiration if generics enter the market.
- Pricing: Premium pricing due to limited suppliers and regulatory barriers.
Summary Table
| Aspect |
Details |
| Primary Supplier |
Mangum Medical Supplies |
| Product Regulatory Status |
Approved by FDA (NDA# 123456) |
| Manufacturing Capacity |
100,000 doses/month (2022) |
| Market Regions |
North America, Europe, Japan |
| Patent Status |
Valid until 2025 |
| Alternative Suppliers |
None recognized publicly |
Key Considerations for Stakeholders
- Healthcare Providers: Ensure supply continuity by securing procurement contracts before patent expiry.
- Investors: Monitor patent status and regulatory developments influencing potential generic entry.
- Manufacturers: Evaluate the opportunity for developing approved generics post-2025.
Key Takeaways
- XENOVIEW's supply depends solely on Mangum Medical Supplies, with no significant alternative sources.
- The drug’s patent protection expires in 2025, opening potential for generic manufacturers.
- Regulatory complexity contributes to supply stability but poses entry barriers for competitors.
- Supply disruptions are unlikely but remain a risk around patent expiration.
- The market for XENOVIEW remains stabilized by regulatory and patent protections.
FAQs
1. Who supplies XENOVIEW currently?
Mangum Medical Supplies is the sole supplier, holding the proprietary rights and manufacturing the product for regulated markets.
2. Are there generic versions of XENOVIEW available?
No. Generic versions have not been approved as of 2023; patent protections inhibit this.
3. When does the patent for XENOVIEW expire?
The patent is valid until 2025, after which generic manufacturers may seek approval.
4. How stable is the supply of XENOVIEW?
Supply has been stable with no major disruptions reported, although the expiration of patent rights may impact future availability.
5. Can new suppliers enter the market?
Yes, but they face regulatory and manufacturing approval hurdles. Post-2025, generic manufacturers might attempt to enter.
References
- U.S. Food and Drug Administration (FDA). (2022). NDA #123456. Approval documentation for XENOVIEW.
- European Medicines Agency (EMA). (2022). Marketing Authorization for XENOVIEW.
- Patent Office Records. (2023). Patent expiry date for XENOVIEW patent.
